Treatment of Antineutrophil cytoplasmic antibody-associated vasculitis - A systematic review

被引:127
作者
Bosch, Xavier
Guilabert, Antonio
Espinosa, Gerard
Mirapeix, Eduard
机构
[1] Univ Barcelona, Hosp Clin, IDIBAPS, Dept Internal Med, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin, IDIBAPS, Dept Dermatol, E-08036 Barcelona, Spain
[3] Univ Barcelona, Hosp Clin, IDIBAPS, Dept Autoimmune Dis, E-08036 Barcelona, Spain
[4] Univ Barcelona, Hosp Clin, IDIBAPS, Dept Nephrol, E-08036 Barcelona, Spain
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2007年 / 298卷 / 06期
关键词
D O I
10.1001/jama.298.6.655
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Immunosuppressive therapies for antineutrophil cytoplasmic antibody ( ANCA) associated vasculitis have greatly advanced patient survival but have turned ANCA-associated vasculitis (AAV) into chronic, relapsing disorders. Long-term treatment and disease-related morbidity are major threats. The last decade has seen a collaborative international effort to determine effective treatment. Objective To analyze the reported evidence on AAV therapy in order to provide physicians with a rational approach for dealing with various clinical scenarios. Data Sources We searched English-language articles on the medical treatment of AAV published between 1966 and March 2007 using MEDLINE. Articles from the reference lists of the most relevant articles retrieved were also analyzed. Study Selection Studies of current available drug treatments or medical interventions for patients with AAV were included. Duplicate publications, case reports, and uncontrolled trials and series including fewer than 10 patients were excluded. Data Synthesis We included 2 meta-analyses, 20 randomized controlled prospective trials, and 62 uncontrolled trials with more than 10 patients or observational studies. Outcome measures and treatment protocols were heterogeneous across trials. Cotrimoxazole can be used alone or in combination with corticosteroids to induce and maintain remission in cases of isolated upper respiratory tract involvement. To induce remission, methotrexate plus corticosteroids can be used instead of cyclophosphamide for patients with generalized, non-organ-threatening disease. When methotrexate is used as maintenance therapy, the likelihood of relapse is high and rigorous monitoring is mandatory. Pulse cyclophosphamide with corticosteroids can be used to induce remission in patients with generalized organ-threatening disease. The combination of azathioprine and daily prednisone is effective in maintaining remission. Plasma exchange is at present the best complement to immunosuppressants in advanced renal disease. In Churg-Strauss syndrome, treatment can be started with high doses of corticosteroids, tapering them when the clinical situation improves. In patients with a high risk of death, cyclophosphamide should be introduced. Conclusions Although AAV therapies should be tailored to the patient's specific clinical situation, evidence for treatment of several disease states is lacking. There is a need for safer and more effective drugs.
引用
收藏
页码:655 / 669
页数:15
相关论文
共 110 条
[1]   Clinical outcome of patients with Wegener's granulomatosis treated with plasma exchange [J].
Aasarod, K ;
Iversen, BM ;
Hammerstrom, J ;
Bostad, L ;
Jorstad, S .
BLOOD PURIFICATION, 2002, 20 (02) :167-173
[2]   Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis [J].
Adu, D ;
Pall, A ;
Luqmani, RA ;
Richards, NT ;
Howie, AJ ;
Emery, P ;
Michael, J ;
Savage, COS ;
Bacon, PA .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1997, 90 (06) :401-409
[3]  
[Anonymous], LEV EV GRAD REC
[4]   15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis:: A six-month open-label trial to evaluate safety and efficacy [J].
Birck, R ;
Warnatz, K ;
Lorenz, HM ;
Choi, M ;
Haubitz, M ;
Grünke, M ;
Peter, HH ;
Kalden, JR ;
Göbel, U ;
Drexler, JM ;
Hotta, O ;
Nowack, R ;
Van der Woude, FJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (02) :440-447
[5]  
Boki KA, 1997, BRIT J RHEUMATOL, V36, P1059
[6]  
Boomsma MM, 2000, ARTHRITIS RHEUM-US, V43, P2025, DOI 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO
[7]  
2-O
[8]   Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis [J].
Booth, A ;
Harper, L ;
Hammad, T ;
Bacon, P ;
Griffith, M ;
Levy, J ;
Savage, C ;
Pusey, C ;
Jayne, D .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (03) :717-721
[9]   Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study [J].
Booth, AD ;
Almond, MK ;
Burns, A ;
Ellis, P ;
Gaskin, G ;
Neild, GH ;
Plaisance, M ;
Pusey, CD ;
Jayne, DRW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :776-784
[10]   Microscopic polyangiitis (microscopic polyarteritis) with late emergence of generalised Wegener's granulomatosis [J].
Bosch, X .
ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 (10) :644-647